

**Date and Time:** *Monday 4<sup>th</sup> February 2013 (10.00 – 4.00pm)*

**Minutes:** to be confirmed

**Guideline Development Group Meeting 4: Dyspepsia & GORD**

**Place:** NICE Offices, 10 Spring Gardens, London SW1A 2BN

**Present:** Peter Barry (Chair) (PB)  
 Hugh Barr (HB)  
 John de Caestecker (JD)  
 Mark Follows (MF)  
 Alex Ford (AF)  
 Ann Harding (AH)  
 Janusz Jankowski (JJ)  
 Mimi McCord (MM)  
 Marco Novelli (MN)

**In attendance:**

NICE Staff:		
Emma Banks (EB) Ben Doak (BD) Katy Harrison (KH) Emma McFarlane (EM)	Gabriel Rogers (GR) Toni Tan (TT) Thomas Wilkinson (TW)	

**Observers:**

--	--	--

**Notes**

Day 1

1. PB welcomed the group to the fourth meeting of this GDG. Declarations of interest were received and recorded. Minutes for the previous meeting were agreed.
2. TT presented a summary of the evidence for review question 2 which asks what characteristics/symptoms of GORD or symptoms suggestive of GORD to indicate endoscopy to exclude Barrett's Oesophagus? The group then discussed all the information presented having noted the low evidence base but recognised there were still some consistency in the evidence. The group further discussed the issues with variation in definitions of Barrett's Oesophagus, differences in current practice, and the quality of endoscopies carried out. Evidence statements were reviewed and changes agreed.

## Notes

3. TW explained the hope was to provide the GDG with an economic evaluation that stratified otherwise well patients to endoscopy based on risk for Barrett's oesophagus and compared the difference in outcomes and costs for future management. However, once economic filters were applied to the search protocol no economic evaluation met the selection criteria shared with the GDG. TW went on to acknowledge given the uncertainty in literature, it is unsurprising that no suitable economic evaluations were found and it was rare to find informative economic evidence for prognostic questions.
4. The group then drafted a number of recommendations for review question 2.
5. Review protocols for questions 1 and 3 were revisited for TT to gain further clarification from the GDG to ensure no overlaps with the clinical areas and recommendations already included in the original guideline (CG17).
6. PB closed the meeting and thanked everyone for attending.

### **Date and venue of the next meeting:**

Next Meeting: 22nd April 2013 at NICE office, City Tower, Piccadilly Plaza, Manchester, M1 4BD